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To the Editor:
I read with deep interest the 
article by Osarogiagbon et al.1 in the 
August issue of the Journal of Thoracic 
Oncology. I would like to congratulate 
the authors on calling the attention 
of the readers to a seemingly minus-
cule technical detail: the proper han-
dling and transporting of lymph nodes 
removed during lung cancer surgery. 
Unfortunately enough, the reference 
list of the article gives the misleading 
impression that no previous attempts 
to solve the problem addressed by the 
authors have been published so far. 
The reality is different. An article on 
a sterile moulded tray with cupped 
containers in the exact topographical 
positions of the hilar and mediastinal 
lymph nodes to assist the surgeon to 
achieve a systematic nodal collection 
was published 5 years ago.2 The article 
is freely downloadable from http://ejcts.
oxfordjournals.org/content/31/2/311. 
The tool has been in clinical use since 
this publication and is the third search 
result when one types lymphnode tray 
in Google search. The application of the 
same principle has led to the production 
of a similar tray representing the cervi-
cal region to be used in ear-nose-throat 
malignancies.3 A Hungarian publication 
with English abstract indexed in the 
Medline4 may have secondary impor-
tance, but the article published in a 
leading journal of the field should have 
not passed unnoticed.
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In Response:
I thank Dr. Molnar for his interest 
and insight into the worldwide problem 
of secure specimen transfer in lung can-
cer surgery. I had been unaware of his 
publications relating to the use of sur-
gical specimen kits to improve lymph 
node collection, but now find his How-
to-do-it article to be succinct, interest-
ing, and quite germane.1
Poor pathologic staging of can-
cer, especially non–small-cell lung can-
cer, is an important international public 
health quality-of-care problem, needful 
of wide acknowledgment and corrective 
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interventions.2,3 Lymph node specimen 
collection kits are a simple and elegant 
solution to this problem.4 There remains 
the additional problem of disseminating 
information about the benefit of these 
kits and more importantly, implement-
ing their routine and proper use. The 
reception of these kits by surgeons and 
pathologists has been very encourag-
ing. I thank Dr. Molnar for his interest 
and willingness to share his expertise.
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To the Editor:
Higgins et al.1 are to be con-
gratulated on their retrospective 
analysis of the implications of lym-
phovascular invasion (LVI) for staging 
Letters to the editor
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and adjuvant therapy in stage IA non–
small-cell lung cancer (NSCLC) 
patients with complete resection. 
Their main conclusion is that the pres-
ence of LVI is significantly associated 
with an increased risk of develop-
ing distant metastases (DM) on uni-
variate and multivariate analysis and 
also of local recurrence on univariate 
analysis. Consequently, they believe 
that adjuvant chemotherapy should be 
considered for these patients because 
DM and local recurrence were associ-
ated with worsening overall survival. 
They criticize the current National 
Comprehensive Cancer Network 
guidelines as somewhat ambiguous in 
this regard, stating that the presence 
of LVI is considered high risk, even 
though the influence of LVI on the 
recommended adjuvant treatment after 
complete resection remains unclear. 
Such ambiguity is clearly referred to 
in the data published by Ettinger et al.2 
The conclusions of Higgins et al.1 are 
shared with additional published data 
on the appropriateness of the indica-
tion for adjuvant chemotherapy for 
these high-risk patients with NSCLC 
stage IA. Tsuchiya et al.3 believe there 
must be a more appropriate valuation 
of the role of LVI as a new target for 
adjuvant chemotherapy in patients 
with NSCLC stage IA. On the basis of 
a meta-analysis of six randomized con-
trolled trials, Hamada et al.4 observed 
a benefit of adjuvant chemotherapy 
in patients with complete resection 
of NSCLC stage IA T1b (diameter > 
2 cm).
Bodendorf et al.5 reported that 
LVI in NSCLC stage IA has strong 
prognostic significance, implying the 
necessity of considering how this will 
reflect on decisions regarding adjuvant 
chemotherapy. In a study of broncho-
genic carcinoma with specific reference 
to the 7th Edition of the TNM classifi-
cation, Igai et al.6 reported that adjuvant 
chemotherapy is indicated for NSCLC 
stage IA p-T1 aN0M0 patients with LVI 
and complete resection. Funai et al.7 are 
convinced that adjuvant chemotherapy 
after complete resection in patients with 
adenocarcinoma stage IA p-T1 aN0M0 
is an unavoidable treatment in the event 
of LVI.
At the 2nd European Lung Cancer 
Conference (Geneva 2010), Ruffini et al.8 
affirmed that LVI is still underestimated, 
given the prognostic outlook and role of 
adjuvant chemotherapy in patients with 
complete resection of stage IA NSCLC.
In their extensive study of the 
relevant prognostic value of LVI in T1a 
and T1b patients, Naito et al.9 strongly 
suggest updating the guidelines con-
cerning the indications for adjuvant 
chemotherapy in NSCLC stage IA radi-
cal resection patients.
In conclusion, current data 
increasingly demonstrate that revi-
sion of the criteria excluding adjuvant 
chemotherapy for patients with radical 
resection for NSCLC stage IA with LVI 
is mandatory. In the new scenario in 
the 2009 TNM classification, the terms 
not indicated and contraindicated must 
be reconsidered in an updated amend-
ment. A risk-guided strategy focused 
on: (a) overall survival, (b) disease-
free survival, and (c) the incidence of 
local recurrence and DM should be 
developed for lung carcinoma patients 
at high risk of these unfavorable devel-
opments. Moreover, referring to spe-
cific patient subgroups guarantees the 
proper respect for the trend to pursue 
personalized treatment making use of 
biomolecular and pathomorphological 
parameters.
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In Response:
The Letter to the Editor by Salvati1 
commenting on the original article by 
Higgins et al.2 and elaborating on the 
adverse prognosis of lymphovascular 
invasion (LVI) in resected non–small-
cell lung cancer raises an important 
issue for current clinical practice: 
the suitability to administer adjuvant 
therapy to patients whose resected 
tumors have LVI, when there are no 
clear guidelines on the topic. Higgins 
et al.2 showed that LVI is associated 
with higher risk of distant metastases 
and shorter long-term survival in a pop-
ulation of patients with predominantly 
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